Dementia: cognitive impact of ADT may hinge on duration

  • Sari Motlagh R & al.
  • J Urol
  • 28 Aug 2020

  • curated by Susan London
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Men with prostate cancer given androgen deprivation therapy (ADT) had significantly elevated risk for all-cause dementia that was driven by use for more than a year.

Why this matters

Key results

  • Relative to peers not given ADT, men with prostate cancer given ADT had elevated risks (all HRs; 95% CIs) for:
    • All-cause dementia: 1.21 (1.11-1.33).
    • Alzheimer’s disease: 1.16 (1.09-1.24).
  • Risk for all-cause dementia differed by ADT duration:
    • Significant when given for >12 months: 1.36 (1.07-1.72).
    • Not significant when given for ≤12 months: 1.06 (0.77-1.28).
  • Risk for Alzheimer’s disease was not significantly elevated whether ADT was given for >12 months or for ≤12 months.

Study design

  • Systematic review and meta-analysis of 14 prospective and retrospective cohort studies and randomized controlled trials among 2,068,315 men with any-stage prostate cancer.
  • Main outcomes: all-cause dementia, Alzheimer’s disease.
  • Funding: None.

Limitations

  • Heterogeneity in ADT type, patient populations.
  • Limited numbers for duration-stratified analyses.
  • Cutoffs other than 12 months were not assessed.
  • Majority of studies conducted in US.
  • Studies using intermittent ADT as control were excluded.